These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Virodene--support misguided. Hugo BW S Afr Med J; 1997 May; 87(5):613. PubMed ID: 9254823 [No Abstract] [Full Text] [Related]
5. Virodene--support misguided. Mahomed F S Afr Med J; 1997 May; 87(5):613-4. PubMed ID: 9254824 [No Abstract] [Full Text] [Related]
6. How Virodene might work--a hypothesis. Epstein E S Afr Med J; 1998 Feb; 88(2):155-6. PubMed ID: 9717503 [No Abstract] [Full Text] [Related]
7. Virodene--support misguided. Spencer DC S Afr Med J; 1997 May; 87(5):613. PubMed ID: 9254822 [No Abstract] [Full Text] [Related]
8. Potential new therapies for the treatment of HIV-1 infection. Condra JH; Miller MD; Hazuda DJ; Emini EA Annu Rev Med; 2002; 53():541-55. PubMed ID: 11818489 [TBL] [Abstract][Full Text] [Related]
9. HIV drug development: the next 25 years. Flexner C Nat Rev Drug Discov; 2007 Dec; 6(12):959-66. PubMed ID: 17932493 [TBL] [Abstract][Full Text] [Related]
10. 124 drugs currently in development. AIDS Patient Care STDS; 1998 Feb; 12(2):149. PubMed ID: 11361916 [No Abstract] [Full Text] [Related]
12. [New attack point in anti-HIV therapy discovered. Docking of viruses to human cells can be prevented]. Baggiolini M Fortschr Med; 1997 Sep; 115(27):48-50. PubMed ID: 9432486 [No Abstract] [Full Text] [Related]
13. Promising investigational drug available to AIDS patients. Bol Asoc Med P R; 1991 Nov; 83(11):508-9. PubMed ID: 1839821 [No Abstract] [Full Text] [Related]
14. Significant reduction in HIV-1 plasma viral load but not in proviral infected cells during sub-optimal antiretroviral therapy. Riva E; Antonelli G; Solmone MC; Turriziani O; Narciso P; Tozzi V; Dianzani F J Biol Regul Homeost Agents; 2000; 14(1):1-3. PubMed ID: 10763882 [TBL] [Abstract][Full Text] [Related]
15. Viramune Expanded Access Program begins. AIDS Patient Care STDS; 1996 Jun; 10(3):186. PubMed ID: 11361629 [No Abstract] [Full Text] [Related]
16. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008]. Zheng PR; Xue H; Xiao ZY; Liu G Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426 [TBL] [Abstract][Full Text] [Related]
17. Experimental and clinical research of HIV-1 resistance in three AIDS patients who had experienced multiple regimens. Lu JF; Li J; Li HP; Liu SY; Zhuang DM; Liu YJ; Bao ZY; Li L; Wu H; Li JY Chin Med J (Engl); 2009 Mar; 122(6):752-4. PubMed ID: 19323948 [No Abstract] [Full Text] [Related]
18. The multiple benefits associated with HIV drug-resistance mutation M184V. Bean P Am Clin Lab; 2002 Mar; 21(2):16-8. PubMed ID: 11993249 [No Abstract] [Full Text] [Related]
19. [The molecular bases of AIDS therapy]. BenÃtez-Bribiesca L Gac Med Mex; 1997; 133(2):151-3. PubMed ID: 9254287 [No Abstract] [Full Text] [Related]
20. Chemokine (C-C motif) receptor 5 entry inhibitors: new class of drugs for acquired immune deficiency syndrome. Jacovina A; New M Mt Sinai J Med; 2008; 75(3):297-8. PubMed ID: 18704982 [No Abstract] [Full Text] [Related] [Next] [New Search]